Trial results

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

NCT04892199 on ClinicalTrials.gov · last registry update 2024-09-25

Closed to new participants; the 104 already enrolled are still being followed. Its estimated completion date, 1 March 2026, has passed with no update to the record. Primary outcome, as filed: The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Anders Fink-Jensen, MD, DMSci

Sponsor type

Other

Enrollment

104

Started

2021-09-01

Primary completion

2026-03-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).

Conditions studied

Metabolic Disturbance · Schizophrenia · Type 2 Diabetes · Clozapine · GLP-1 · Olanzapine

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.